AXIM Biotechnologies (AXIM Biotech) cannabinoid research and development says it has received positive pharmacokinetic (PK) data results on its CanChew Plus CBD Gum. As a result, the company said it will start clinical trials on the gum for alleviating the symptoms of irritable bowel syndrome (IBS).  IBS patient trial Volunteers took part in a study […]

by

NEW YORK, January 5, 2017 /PRNewswire/ — http://www.Financialbuzz.com – Over the recent few years, particularly in 2016, the legal cannabis industry has accomplished some significant milestones. Most importantly is the change of public opinion regarding the use of cannabis, both for medical and recreational purposes. Before the November 8th elections where five states voted on […]

by

REDONDO BEACH, CA–(Marketwired – Jan 5, 2017) – SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces an article discussing the recent, successful completion of AXIM® Biotechnologies’ ( OTCQB : AXIM ) pharmacokinetic (PK) study of its CanChew Plus® CBD Gum. The single-dose study on 10 mg […]

by

As a result of this election cycle, as five additional states voted in favor legalization, including California, the largest market for the industry, The Drug Enforcement Administration also changed its approach. The DEA has previously declined to reschedule cannabis under the Controlled Substances Act, has now made easier access for research, and upping the number […]

by

As a result of this election cycle, as five additional states voted in favor legalization, including California, the largest market for the industry, The Drug Enforcement Administration also changed its approach. The DEA has previously declined to reschedule cannabis under the Controlled Substances Act, has now made easier access for research, and upping the number […]

by

JUDY WOODRUFF:  With recreational marijuana now legal in eight states, a serious health and safety question about the potency of the psychoactive drug in cannabis, known as THC, are emerging.  In Colorado, some marijuana products contain 90 percent pure THC, with little research documenting the physical and mental effects on consumers. This week, the state’s […]

by

NEW YORK, Jan. 04, 2017 (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (AXIM® Biotech) (AXIM), a world leader in cannabinoid research and development, received positive pharmacokinetic (PK) data results on its CanChew Plus® CBD Gum, and gears up for clinical trial on alleviating the symptom of irritable bowel syndrome (IBS). The single dose study on 10 […]

by

NEW YORK, Jan. 04, 2017 (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (AXIM® Biotech) (AXIM), a world leader in cannabinoid research and development, received positive pharmacokinetic (PK) data results on its CanChew Plus® CBD Gum, and gears up for clinical trial on alleviating the symptom of irritable bowel syndrome (IBS). The single dose study on 10 […]

by

NEW YORK, Jan. 04, 2017 (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (AXIM® Biotech) (AXIM), a world leader in cannabinoid research and development, received positive pharmacokinetic (PK) data results on its CanChew Plus® CBD Gum, and gears up for clinical trial on alleviating the symptom of irritable bowel syndrome (IBS). The single dose study on 10 […]

by

Shares of Agile Therapeutics Inc. (AGRX) got pounded in extended trading on Tuesday despite positive results from SECURE, the company’s phase III trial of its once-weekly contraceptive patch Twirla. SECURE was conducted to address issues raised by the FDA in its 2013 Complete Response Letter to the company. In the SECURE trial, the PEARL-index score […]

by

Shares of Agile Therapeutics Inc. (AGRX) got pounded in extended trading on Tuesday despite positive results from SECURE, the company’s phase III trial of its once-weekly contraceptive patch Twirla. SECURE was conducted to address issues raised by the FDA in its 2013 Complete Response Letter to the company. In the SECURE trial, the PEARL-index score […]

by

Shares of Agile Therapeutics Inc. (AGRX) got pounded in extended trading on Tuesday despite positive results from SECURE, the company’s phase III trial of its once-weekly contraceptive patch Twirla. SECURE was conducted to address issues raised by the FDA in its 2013 Complete Response Letter to the company. In the SECURE trial, the PEARL-index score […]

by

Zynerba Pharmaceuticals Inc. (ZYNE) announced Tuesday morning that it has initiated its exploratory Phase 2 clinical trial of ZYN002 cannabidiol gel in children with Fragile X syndrome. Zynerba Pharmaceuticals climbed throughout the second half of Tuesday’s session and closed up by 2.36 at $17.95 on above average volume. The stock broke out of a month […]

by

Zynerba Pharmaceuticals Inc. (ZYNE) announced Tuesday morning that it has initiated its exploratory Phase 2 clinical trial of ZYN002 cannabidiol gel in children with Fragile X syndrome. Zynerba Pharmaceuticals climbed throughout the second half of Tuesday’s session and closed up by 2.36 at $17.95 on above average volume. The stock broke out of a month […]

by